Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ioannis Parodis

Showing results (31-40 of 189) with videos related to

Pageof 19
Sort By:
Rheumatology (Oxford, England)|May 25, 2023
Belimumab and antimalarials combined against renal flares in patients treated for extra-renal systemic lupus erythematosus: results from 4 phase III clinical trialsAlvaro Gomez, Sandra Jägerback, Christopher Sjöwall, et al.
Annals of the Rheumatic Diseases|February 6, 2026
Belimumab induces early and sustained resolution of lupus arthritisNicolai Leuchten, Ioannis Parodis, Ralph Brinks, et al.
International Journal of Molecular Sciences|January 10, 2026
Lessons Learnt from the Belimumab Trials in Systemic Lupus ErythematosusLeonardo Palazzo, Alexander Tsoi, Dionysis Nikolopoulos, et al.
Annals of the Rheumatic Diseases|January 6, 2019
Established organ damage reduces belimumab efficacy in systemic lupus erythematosusIoannis Parodis, Alvaro Gomez, Sharzad Emamikia, et al.
Best Practice & Research. Clinical Rheumatology|November 19, 2013
Biologics in SLE: towards new approachesRonald F van Vollenhoven, Ioannis Parodis, Adrian Levitsky
Current Vascular Pharmacology|December 28, 2019
Cardiovascular Disease in Systemic Lupus Erythematosus: Recent Data on Epidemiology, Risk Factors and PreventionMyrto Kostopoulou, Dionysis Nikolopoulos, Ioannis Parodis, et al.
Rheumatology International|August 8, 2024
Neuropsychiatric involvement in systemic lupus erythematosus contributes to organ damage beyond the nervous system: a post-hoc analysis of 5 phase III randomized clinical trialsDionysis Nikolopoulos, Nursen Cetrez, Julius Lindblom, et al.
Lupus Science & Medicine|February 15, 2024
Clinical trial outcomes for SLE: what we have and what we needLaurent Arnaud, Ioannis Parodis, Hervé Devilliers, et al.
Rheumatology (Oxford, England)|February 22, 2025
Treat-to-target in SLE: is serology important? Results from an integrated analysis of five randomized clinical trials of belimumabAlvaro Gomez, Julius Lindblom, Ioannis Parodis, et al.
Autoimmunity Reviews|August 25, 2023
When should targeted therapies be used in the treatment of lupus nephritis: Early in the disease course or in refractory patients?Ioannis Parodis, Roberto Depascale, Andrea Doria, et al.
Pageof 19

Showing results (31-40 of 189) with videos related to

Sort By:
Pageof 19
Rheumatology (Oxford, England)|May 25, 2023
Belimumab and antimalarials combined against renal flares in patients treated for extra-renal systemic lupus erythematosus: results from 4 phase III clinical trialsAlvaro Gomez, Sandra Jägerback, Christopher Sjöwall, et al.
Annals of the Rheumatic Diseases|February 6, 2026
Belimumab induces early and sustained resolution of lupus arthritisNicolai Leuchten, Ioannis Parodis, Ralph Brinks, et al.
International Journal of Molecular Sciences|January 10, 2026
Lessons Learnt from the Belimumab Trials in Systemic Lupus ErythematosusLeonardo Palazzo, Alexander Tsoi, Dionysis Nikolopoulos, et al.
Annals of the Rheumatic Diseases|January 6, 2019
Established organ damage reduces belimumab efficacy in systemic lupus erythematosusIoannis Parodis, Alvaro Gomez, Sharzad Emamikia, et al.
Best Practice & Research. Clinical Rheumatology|November 19, 2013
Biologics in SLE: towards new approachesRonald F van Vollenhoven, Ioannis Parodis, Adrian Levitsky
Current Vascular Pharmacology|December 28, 2019
Cardiovascular Disease in Systemic Lupus Erythematosus: Recent Data on Epidemiology, Risk Factors and PreventionMyrto Kostopoulou, Dionysis Nikolopoulos, Ioannis Parodis, et al.
Rheumatology International|August 8, 2024
Neuropsychiatric involvement in systemic lupus erythematosus contributes to organ damage beyond the nervous system: a post-hoc analysis of 5 phase III randomized clinical trialsDionysis Nikolopoulos, Nursen Cetrez, Julius Lindblom, et al.
Lupus Science & Medicine|February 15, 2024
Clinical trial outcomes for SLE: what we have and what we needLaurent Arnaud, Ioannis Parodis, Hervé Devilliers, et al.
Rheumatology (Oxford, England)|February 22, 2025
Treat-to-target in SLE: is serology important? Results from an integrated analysis of five randomized clinical trials of belimumabAlvaro Gomez, Julius Lindblom, Ioannis Parodis, et al.
Autoimmunity Reviews|August 25, 2023
When should targeted therapies be used in the treatment of lupus nephritis: Early in the disease course or in refractory patients?Ioannis Parodis, Roberto Depascale, Andrea Doria, et al.
Pageof 19